AVID BIOSERVICES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.42 USD | +2.06% |
|
+11.38% | +29.54% |
| Apr. 30 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
| Apr. 29 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
Valuation
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 268.6 | 344.5 | 1,302 | 831.1 | 1,129 | 523.7 | - | - |
| Enterprise Value (EV) 1 | 268.6 | 344.5 | 1,302 | 831.1 | 1,129 | 523.7 | 523.7 | 523.7 |
| P/E ratio | -29.9 x | -22.6 x | 357 x | 7.32 x | 1,805 x | -26 x | -44 x | 138 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.01 x | 5.77 x | 13.6 x | 6.95 x | 7.56 x | 3.77 x | 3.19 x | 2.55 x |
| EV / Revenue | 5.01 x | 5.77 x | 13.6 x | 6.95 x | 7.56 x | 3.77 x | 3.19 x | 2.55 x |
| EV / EBITDA | -93.4 x | -46 x | 83 x | 27.3 x | 52 x | 289 x | 27.6 x | 13.6 x |
| EV / FCF | -20.5 x | 171 x | 61.1 x | -17.7 x | -12.5 x | -26.9 x | -62.3 x | -5,237 x |
| FCF Yield | -4.88% | 0.58% | 1.64% | -5.65% | -8.02% | -3.72% | -1.6% | -0.02% |
| Price to Book | - | - | 16.4 x | 5.44 x | 5.97 x | 2.89 x | 3.72 x | 3.34 x |
| Nbr of stocks (in thousands) | 56,075 | 56,482 | 60,829 | 61,744 | 62,547 | 63,480 | - | - |
| Reference price 2 | 4.790 | 6.100 | 21.40 | 13.46 | 18.05 | 8.250 | 8.250 | 8.250 |
| Announcement Date | 6/27/19 | 6/30/20 | 6/29/21 | 6/29/22 | 6/21/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Aprile | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 53.6 | 59.7 | 95.87 | 119.6 | 149.3 | 139.1 | 164 | 205.7 |
| EBITDA 1 | -2.876 | -7.494 | 15.7 | 30.43 | 21.7 | 1.812 | 19.01 | 38.64 |
| EBIT 1 | -5.622 | -10.58 | 12.24 | 15.42 | 3.601 | -17.59 | -4.331 | 17.04 |
| Operating Margin | -10.49% | -17.73% | 12.77% | 12.89% | 2.41% | -12.64% | -2.64% | 8.29% |
| Earnings before Tax (EBT) 1 | -5.34 | -10.47 | 11.21 | 12.66 | 2.003 | -24.84 | -15.21 | 0.128 |
| Net income 1 | -8.901 | -15.15 | 3.318 | 127.7 | 0.56 | -20.1 | -11.94 | -0.039 |
| Net margin | -16.61% | -25.38% | 3.46% | 106.75% | 0.38% | -14.45% | -7.28% | -0.02% |
| EPS 2 | -0.1600 | -0.2700 | 0.0600 | 1.840 | 0.0100 | -0.3175 | -0.1875 | 0.0600 |
| Free Cash Flow 1 | -13.1 | 2.015 | 21.32 | -46.95 | -90.52 | -19.5 | -8.4 | -0.1 |
| FCF margin | -24.43% | 3.38% | 22.24% | -39.25% | -60.65% | -14.02% | -5.12% | -0.05% |
| FCF Conversion (EBITDA) | - | - | 135.82% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | 642.5% | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 6/27/19 | 6/30/20 | 6/29/21 | 6/29/22 | 6/21/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: April | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 26.11 | 31.51 | 31.23 | 36.69 | 34.76 | 38.02 | 39.8 | 37.73 | 25.4 | 33.8 | 42.14 | 40.72 | 34.32 | 40.68 | 48.18 |
| EBITDA 1 | 5.18 | 4.293 | 5.893 | 6.188 | 1.885 | 7.367 | 6.265 | 2.791 | -5.972 | -1.117 | 5.536 | 4.288 | 0.9253 | 4.447 | 8.014 |
| EBIT 1 | 4.153 | 3.269 | 1.069 | 2.735 | -2.684 | 2.718 | 0.832 | -2.163 | -11.22 | -4 | -0.1985 | -1.403 | -5.418 | -1.531 | 2.096 |
| Operating Margin | 15.91% | 10.38% | 3.42% | 7.45% | -7.72% | 7.15% | 2.09% | -5.73% | -44.19% | -11.83% | -0.47% | -3.45% | -15.78% | -3.76% | 4.35% |
| Earnings before Tax (EBT) 1 | 3.522 | 2.248 | 0.587 | 2.267 | -3.242 | 2.53 | 0.448 | -2.68 | -11.89 | -7.058 | -3.172 | -4.14 | -8.156 | -4.268 | -0.6415 |
| Net income 1 | 3.522 | 2.248 | 115.6 | 1.564 | -1.156 | 0.461 | -0.309 | -2.093 | -9.509 | -6.006 | -2.458 | -3.196 | -6.32 | -3.314 | -0.511 |
| Net margin | 13.49% | 7.13% | 370.2% | 4.26% | -3.33% | 1.21% | -0.78% | -5.55% | -37.44% | -17.77% | -5.83% | -7.85% | -18.41% | -8.14% | -1.06% |
| EPS 2 | 0.0600 | 0.0400 | 1.650 | 0.0200 | -0.0200 | 0.0100 | - | -0.0300 | -0.1500 | -0.0900 | -0.0375 | -0.0500 | -0.0950 | -0.0550 | -0.005000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/7/21 | 3/8/22 | 6/29/22 | 9/6/22 | 12/6/22 | 3/13/23 | 6/21/23 | 9/7/23 | 12/7/23 | 3/6/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -13.1 | 2.02 | 21.3 | -46.9 | -90.5 | -19.5 | -8.4 | -0.1 |
| ROE (net income / shareholders' equity) | -16.4% | - | 18.7% | 19.2% | 0.31% | -11.2% | -5.6% | 3.2% |
| ROA (Net income/ Total Assets) | - | - | 3.64% | 6.97% | 0.13% | -4.4% | -2.2% | 1.4% |
| Assets 1 | - | - | 91.03 | 1,833 | 440.6 | 456.7 | 542.8 | -2.786 |
| Book Value Per Share 2 | - | - | 1.310 | 2.480 | 3.020 | 2.850 | 2.220 | 2.470 |
| Cash Flow per Share 2 | -0.0300 | - | 0.2500 | 0.1300 | -0.2000 | -0.1400 | 0.0300 | 0.2600 |
| Capex 1 | 1.5 | 3.81 | 9.86 | 56.4 | 77.6 | 31.6 | 6 | 7.03 |
| Capex / Sales | 2.8% | 6.39% | 10.29% | 47.17% | 52.01% | 22.72% | 3.66% | 3.42% |
| Announcement Date | 6/27/19 | 6/30/20 | 6/29/21 | 6/29/22 | 6/21/23 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.25
USD
Average target price
12.5
USD
Spread / Average Target
+51.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.92% | 524M | |
| -3.89% | 88.14B | |
| +1.45% | 40.51B | |
| -15.94% | 31.67B | |
| +52.66% | 24.62B | |
| -14.50% | 15.65B | |
| -14.38% | 12.07B | |
| -9.12% | 11.97B | |
| -42.56% | 11.61B | |
| +4.87% | 8.81B |
- Stock Market
- Equities
- CDMO Stock
- Financials Avid Bioservices, Inc.